NCT05438147View on ClinicalTrials.gov

Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms

NACompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

September 6, 2022

Study Completion Date

September 6, 2022

Conditions
Multiple SclerosisMild Cognitive ImpairmentCancer
Interventions
OTHER

CT-100 DiNaMo

Active Treatment (Study App)

OTHER

Care-as-Usual

Care-As-Usual control

Trial Locations (1)

10013

Click Therapeutics, New York

Sponsors
All Listed Sponsors
lead

Click Therapeutics, Inc.

INDUSTRY

NCT05438147 - Effects of a CT-100 DiNaMo Component on Cognitive Functioning and Mood Symptoms | Biotech Hunter | Biotech Hunter